Spruce Non Operating Income Net Other from 2010 to 2026
| SPRB Stock | USD 77.55 2.31 2.89% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 1.8 M | Current Value 947.6 K | Quarterly Volatility 641.2 K |
Check Spruce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spruce Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 3.8 M, Depreciation And Amortization of 48.2 K or Interest Expense of 305.3 K, as well as many indicators such as Price To Sales Ratio of 7.89, Dividend Yield of 0.0 or PTB Ratio of 0.55. Spruce financial statements analysis is a perfect complement when working with Spruce Biosciences Valuation or Volatility modules.
Spruce | Non Operating Income Net Other | Build AI portfolio with Spruce Stock |
Analyzing Spruce Biosciences's Non Operating Income Net Other over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Non Operating Income Net Other has evolved provides context for assessing Spruce Biosciences's current valuation and future prospects.
Latest Spruce Biosciences' Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of Spruce Biosciences Common over the last few years. It is Spruce Biosciences' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spruce Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
Spruce Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | 646,535 | |
| Geometric Mean | 401,474 | |
| Coefficient Of Variation | 99.17 | |
| Mean Deviation | 577,869 | |
| Median | 200,000 | |
| Standard Deviation | 641,171 | |
| Sample Variance | 411.1B | |
| Range | 1.6M | |
| R-Value | 0.78 | |
| Mean Square Error | 168.4B | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | 99,645 | |
| Total Sum of Squares | 6.6T |
Spruce Non Operating Income Net Other History
About Spruce Biosciences Financial Statements
Spruce Biosciences stakeholders use historical fundamental indicators, such as Spruce Biosciences' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Spruce Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spruce Biosciences' assets and liabilities are reflected in the revenues and expenses on Spruce Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spruce Biosciences Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | 1.8 M | 947.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Common Stock:Check out the analysis of Spruce Biosciences Correlation against competitors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Spruce Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (84.32) | Revenue Per Share | Quarterly Revenue Growth (0.76) | Return On Assets | Return On Equity |
Understanding Spruce Biosciences Common requires distinguishing between market price and book value, where the latter reflects Spruce's accounting equity. The concept of intrinsic value—what Spruce Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Spruce Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spruce Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.